Sword Health plans to buy Headspace, filing saysnews2026-08-25T22:03:01+00:00August 25th, 2026|Endpoints News|
Amgen, academic centers weigh new FDA pilot to speed early drug trialsnews2026-08-25T18:37:14+00:00August 25th, 2026|Endpoints News|
J&J’s Imaavy wins label expansion; Two approvals in Japannews2026-08-25T14:44:05+00:00August 25th, 2026|Endpoints News|
FDA approves Jazz’s Ziihera in frontline gastric cancernews2026-08-25T14:37:56+00:00August 25th, 2026|Endpoints News|
ARCH and Population Health join China blitz with Haisco dealnews2026-08-25T14:15:05+00:00August 25th, 2026|Endpoints News|
OmicsBank raises $2.25M to bring overseas patient data to biopharmanews2026-08-25T13:00:57+00:00August 25th, 2026|Endpoints News|
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorgnews2026-08-25T12:00:45+00:00August 25th, 2026|Endpoints News|
Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goalnews2026-08-24T20:00:33+00:00August 24th, 2026|Endpoints News|
DC judge rejects Merck’s IRA case more than three years after it was filednews2026-08-24T16:44:26+00:00August 24th, 2026|Endpoints News|
Regenxbio hit with another clinical hold for Hunter syndrome gene therapynews2026-08-24T15:17:56+00:00August 24th, 2026|Endpoints News|
